Augmenting strategies in clozapine-resistant schizophrenia

CNS Drugs

Volumn 20, Issue 2, 2006, Pages 171-

  Remington, Gary ^a,b   Saha, Amitabha ^c   Chong, Siow Ann ^c   Shammi, Chekkera ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ICOSAPENTAENOIC ACID ETHYL ESTER;

CLINICAL TRIAL; DATA ANALYSIS; HUMAN; LETTER; MEDICAL LITERATURE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POPULATION RESEARCH; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA;

EID: 32944455694     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200620020-00008     Document Type: Letter

References (5)

1. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19 (10): 843-72
2. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-15
3. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-8
4. Fenton W, Dickerson FB, Boronow JJ, et al. Placebo-controlled trial of omega-3 fatty acid in schizophrenia. Schizophrenia Research 2001; 49 Suppl 1-2: 227
5. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18